Zymeworks will pay $17.00/share (~$929M) for Theravance, prioritizing Yupelri-linked profitability and planned post-close ...
Resilient field models emphasize continuous territory coverage via agile deployment, blending scalable virtual reach with ...
In today's Pharmaceutical Executive Daily, AbbVie announces a $10.9 billion agreement to acquire Apogee Therapeutics, adding ...
In today's Pharmaceutical Executive Daily, the FDA approves Gilead's Trodelvy for the first-line treatment of metastatic ...
New data from ADA 2026 reveal that assumptions around age, weight, and gestational history are leaving too many T1D patients ...
Capvaxive uniquely adds eight adult-predominant invasive serotypes absent from other approved pneumococcal vaccines, ...
For pharmaceutical executives, the transition from just extending to fully optimizing life is a defining commercial ...
Amy Prashker | Authors | Pharmaceutical Executive delivers strategic insights for pharma leaders, covering commercialization, market access, R&D, and leadership to drive success.
FDA approved Utebzi, an oral carbapenem antibiotic developed by GSK in partnership with Spero Therapeutics, for the treatment ...
They want to make sure we've got more control over that supply chain, so DARPA and the federal government are really ...
Clinical Affairs plays a central role in ensuring that CGM promotional claims are accurate, evidence-based, and compliant. By ...
Approval establishes sacituzumab govitecan as a first-line option across PD-L1 strata, including monotherapy when checkpoint inhibitors are unsuitable and combination therapy for PD-L1 CPS ≥10 tumors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results